Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Intravenous Difelikefalin in Chinese Hemodialysis Subjects
NCT05885763Phase 1Completed
- Sponsor
- CSL Vifor
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of difelikefalin in chronic kidney disease (CKD), sponsored by CSL Vifor. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) - Dose 1 at 1 week, Time to Maximum Plasma Concentration (Tmax) - Dose 1 at 1 week and 10 more. Started Jun 2023; status: completed.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05885763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885763.